Baltimore Business Journal - Oct. 3, 2011 by Alexander Jackson l Staff Reporter

Baltimore’s Gliknik Inc. has won a National Cancer Institute contract for up to $1.5 million.

The biopharmaceuticals company will use the Small Business Innovation Research Phase II contract to continue development of its “Stradobody” platform, a kind of therapy for patients with cancer and immune disorders.

Meanwhile, the company has drawn more investment from private sources as of late. In August, Gliknik raised more than $2 million from private investors.

Gliknik, which is located at the University of Maryland, Baltimore’s BioPark, has now raised more than $10 million, the company said Monday.

With its new SBIR Phase II contract, Gliknik has raised more than $2.5 million in grants and contracts from Maryland and federal sources since its founding in 2007.

Gliknik also is the second Baltimore biotech company to announce within the past week that it has won National Cancer Institute funding. BioMarker Strategies, another company developing a cancer treatment, was awarded $200,000 from the federal research organizaiton that eventually could lead to an additional $1.5 million award.

Last month, the National Cancer Institute dangled $8 million in SBIR contract grants in front of biotech companies.